Results 161 to 170 of about 125,339 (239)

GLP-1 Receptor Agonists in Brazil: Landscape of Consumption, Safety and Regulation. [PDF]

Diabetes Obes Metab
Hurtado RL, Amato AA, de Luca Corrêa H, Silveira D.   +3 more
europepmc   +1 more source

The Expanding Landscape of Microbiota Medicine: Indications, Therapeutic Modalities, and the Path Towards Integrative Microbiome‐Targeting Healthcare

Microbiota Medicine Research, EarlyView.
ABSTRACT The growing recognition of the microbiome's role in human health has propelled the emergence of microbiota medicine—a new discipline integrating microbiology, multi‐omics, and clinical science. Advances in sequencing, data integration, and interventions such as fecal microbiota transplantation (FMT) have transitioned the field from ...
Min Dai, Yisha Lin, Renyou Gan, Xiaotao Shen, Shin Young Park, Sunjae Lee, Qi Su   +6 more
wiley   +1 more source

Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations. [PDF]

Diabetes Metab Syndr Obes
Yılmaz N, Bastemir M.
europepmc   +1 more source

Influence of dietary intake and eating patterns on reactive hypoglycemic events in patients postesophagectomy: A prospective observational study using continuous glucose monitoring

Nutrition in Clinical Practice, EarlyView.
Abstract Background Esophagectomy causes anatomical changes that can lead to rapid food transit and reactive hypoglycemia (RH). Patients are advised on eating patterns postesophagectomy to prevent RH, but its true incidence and the impact of dietary recommendations remain under‐researched.
Rachel O'Kelly, Elaine Quigley, Katie Byrne, Mistura A. Kareem, Niamh Ni Mhaoinigh, Paul Healy, Michelle Fanning, John V. Reynolds, Claire L. Donohoe, Suzanne L. Doyle   +9 more
wiley   +1 more source

Nutritional Vulnerability in RYGB Unmasked by GLP-1 Therapy. [PDF]

ACG Case Rep J
Madej J, Gonzaga ER, Naveed M.
europepmc   +1 more source

Exploring the disease burden and quality of life in patients with short bowel syndrome with intestinal failure: Insights from exit interviews in the glepaglutide EASE SBS‐1 phase 3 trial

Nutrition in Clinical Practice, EarlyView.
Abstract Background A randomized, double‐blind, placebo‐controlled trial was conducted to evaluate efficacy and safety of glepaglutide in patients who have short bowel syndrome with intestinal failure (SBS‐IF). At the end of the trial, exit interviews were conducted to explore participants' experiences and to assess the impact of the disease and ...
David F. Mercer, Constance Mubekapi‐Musadaidzwa, Bitten Kloster, Mark Berner‐Hansen, Anna Rydén, Palle Bekker Jeppesen   +5 more
wiley   +1 more source

Interpreting Pregnancy Risk After GLP-1 Receptor Agonists Discontinuation. [PDF]

Diabetes Obes Metab
Scairati R, Newman C, Dunne FP, Colao A.
europepmc   +1 more source

Endoscopic small bowel therapies for type 2 diabetes

Nutrition in Clinical Practice, EarlyView.
Abstract Type 2 diabetes is a global epidemic despite current medical treatments. Many patients are not responsive to medications, and patients with obesity are hesitant about bariatric surgery. Studies investigating the metabolic effects of Roux‐en‐Y gastric bypass have increasingly demonstrated that the duodenum plays a key role in the ...
Roma Patel, Zehra Naseem, Prisha Gattu, Stephen Firkins, Roberto Simons‐Linares   +4 more
wiley   +1 more source

The promise of GLP-1 receptor agonists for neurodegenerative diseases. [PDF]

J Clin Invest
Athauda D, Greig NH, Meissner WG, Foltynie T, Gandhi S.   +4 more
europepmc   +1 more source

What Are the Impacts of GLP‐1 Drugs in Patients Needing Head/Neck Surgery?

The Laryngoscope, EarlyView.
Chelsea Gelboin‐Burkhart, Liam Gallagher, Bridget Ebert, Samir S. Khariwala   +3 more
wiley   +1 more source